Hopu Investments is an alternative asset manager specializing in large-scale proprietary buyouts and large-ticket investments across Asia, with a historical focus on China. The firm aims for strong influence and value creation in sectors such as technology, logistics, consumer goods, and financial services, increasingly pivoting to an Asia-wide strategy.
67% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (67% of deals). Average disclosed round size is $198.3M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
$15B
Top Stage
Series C
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| LLyndra Therapeutics Inc. | Series C | $55M | Jan 2019 |
| GG7 | Growth | $320M | Dec 2018 |
 I-Mab Biopharma | Series C | $220M | Jun 2018 |
Top Co-Investors
Hillhouse Capital1 shared
CDH Investments1 shared
Ally Bridge Group1 shared
EDBI1 shared
Tencent Investment1 shared
Bank of China Group Investment1 shared
Polaris Venture Partners1 shared
Gilead Sciences1 shared
Invus1 shared
Bill & Melinda Gates Foundation1 shared
Last updated: 16 April 2026